Hepatitis C is a chronic infection associated with considerable morbidity and mortality. In recent years, there has been a shift in treatment paradigm with the discovery and approval of agents that target specific proteins vital for hepatitis C replication. The NS3/4A inhibitors simeprevir and paritaprevir, the NS5A inhibitors ombitasvir, ledipasvir, and daclatasvir, and the NS5B inhibitors sofosbuvir and dasabuvir have been newly FDA approved and incorporated as first-line agents into the latest IDSA-AASLD guidelines for Hepatitis C treatment. Used in combination, these agents produce higher rates of sustained virologic response and less adverse effects than historical options, along with limited rates of resistance. Pertinent clinical data, pharmacology, and pharmacokinetics are reviewed for these new direct acting antiviral agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/17512433.2016.1129272 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Direct Acting Antivirals (DAA) therapy in patients with recurrent hepatitis C after liver and kidney transplantation: a cross-sectional study.
Front Med (Lausanne)
October 2024
Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Background And Objectives: Direct-acting antiviral (DAA) agents are now widely used to treat patients with hepatitis C infection (HCV) and effectively increase their sustained virologic response (SVR). However, the literature seems to lack or deficient evidence of DAA efficacy in more complicated patients, especially those with HCV reinfection after liver transplantation (LT) or liver-kidney (hepatorenal) transplantation (LKT). This study aimed to retrospectively evaluate the effectiveness of two different DAA regimens in LT and LKT patients with HCV reinfection.
View Article and Find Full Text PDFHigh efficacy and safety of direct-acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam.
Pharmacol Res Perspect
October 2024
Department of Clinical Pharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment through their high cure rates and improved safety profiles. We aimed to evaluate the efficacy and safety, and identify the optimal combination, of DAAs for the treatment of chronic HCV. A retrospective study was conducted of 613 patients with chronic HCV who were treated with DAAs.
View Article and Find Full Text PDFFDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells.
Biomed Pharmacother
October 2024
Biomolecular NMR laboratory. Department of Inorganic and Organic Chemistry. Universitat de Barcelona (UB), Baldiri Reixac, 10-12, Barcelona 08028, Spain. Electronic address:
Direct-acting antivirals ledipasvir (LDV) and daclatasvir (DCV) are widely used as part of combination therapies to treat Hepatitis C infections. Here we show that these compounds inhibit the proliferation, invasion, and colony formation of triple-negative MDA-MB-231 breast cancer cells, SRC-transduced SW620 colon cancer cells and SRC- transduced NIH3T3 fibroblasts. DCV also inhibits the expression of PDL-1, which is responsible for resistance to immunotherapy in breast cancer cells.
View Article and Find Full Text PDFAnalysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors.
Sci Rep
July 2024
Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8‑35‑1 Sakuragaoka, Kagoshima, 890‑8544, Japan.
Article Synopsis
- Resistance-associated substitutions (RASs) in hepatitis C virus (HCV) can significantly reduce the effectiveness of direct-acting antivirals (DAAs), particularly in patients experiencing treatment failure.
- In a study using a subgenomic replicon system, specific RASs were found to have extremely high levels of resistance to several DAAs, showcasing the varying degrees of resistance among different mutations.
- The research indicates that combining pibrentasvir with sofosbuvir may effectively treat HCV infections with these resistance mutations, potentially leading to successful eradication.
Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India.
J Clin Exp Hepatol
December 2023
Department of Hepatology, Institute of Liver Diseases, Hepato-Pancreato-Biliary Surgery and Transplant, Global Hospitals, Mumbai, India.
Background And Aim: Hepatitis C virus (HCV) treatment fails to achieve sustained virological response at 12 weeks (SVR12) in 5-10 % and requires retreatment with second-line drugs. We report our experience of sofosbuvir/velpatasvir/voxilaprevir use for HCV retreatment in a small cohort of difficult-to-treat Indian patients.
Methods: We reviewed our HCV databases to identify the patients who had failed to achieve SVR12 after treatment with sofosbuvir in combination with either daclatasvir, ledipasvir, or velpatasvir with/without ribavirin on one or more occasions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!